Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for AVITA Medical (RCEL) over the last 4 years, with Q4 2025 value amounting to $2.0 million.

  • AVITA Medical's Change in Acquisitions & Divestments fell 8000.0% to $2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $27.5 million, marking a year-over-year decrease of 6137.64%. This contributed to the annual value of $27.5 million for FY2025, which is 6137.64% down from last year.
  • As of Q4 2025, AVITA Medical's Change in Acquisitions & Divestments stood at $2.0 million, which was down 8000.0% from $3.5 million recorded in Q3 2025.
  • In the past 5 years, AVITA Medical's Change in Acquisitions & Divestments registered a high of $24.3 million during Q1 2023, and its lowest value of $2.0 million during Q4 2025.
  • Moreover, its 4-year median value for Change in Acquisitions & Divestments was $11.4 million (2022), whereas its average is $12.5 million.
  • Per our database at Business Quant, AVITA Medical's Change in Acquisitions & Divestments soared by 90000.0% in 2024 and then crashed by 8541.67% in 2025.
  • Over the past 4 years, AVITA Medical's Change in Acquisitions & Divestments (Quarter) stood at $11.9 million in 2022, then rose by 19.05% to $14.2 million in 2023, then decreased by 29.33% to $10.0 million in 2024, then crashed by 80.0% to $2.0 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $2.0 million for Q4 2025, versus $3.5 million for Q3 2025 and $11.0 million for Q2 2025.